Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TXA vs TXA plus topical batroxobin for blood loss in adolescent idiopathic scoliosis surgery
ChiCTR2500114559Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2025
- Modality
- Small Molecules, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tranexamic acid and batroxobin in adolescent idiopathic scoliosis (AIS) (3 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Total blood loss. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
tranexamic acidbatroxobin
03
Conditions
adolescent idiopathic scoliosis (AIS)
Beyond the preview
Go deeper on ChiCTR2500114559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114559.